5 recruiting, 3 not yet recruiting, 1 active not recruiting, 1 terminated. 10 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 5, Not yet recruiting 3, Active not recruiting 1, Terminated 1 |
| Phase 1 | 3 | Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
Follow CRC (Colorectal Cancer): new trials by email Literature Review of CRC (Colorectal Cancer) trials Research Report on CRC (Colorectal Cancer)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Tunlametinib Combination Therapy in the Treatment of Second-line and Above Metastatic Colorectal Cancer Arm1, Arm 2, Arm 3 - CRC (Colorectal Cancer), BRAF | Phase 2 | Not yet recruiting | Sun Yat-sen University | 91 | 2026-11-30 | 2026-07-21 |
| A Study to Evaluate INCA33890 in the Treatment of Circulating Tumor DNA-Positive Stage II/III Microsatellite Stable Colorectal Cancer After Curative Resection and Chemotherapy INCA33890 - CRC (Colorectal Cancer) | Phase 2 | Not yet recruiting | Incyte Corporation | 40 | 2026-10-26 | 2026-09-22 |
| Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM SCRT, Retlirafusp alfa Injection, Bevacizumab - CRC (Colorectal Cancer) | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 60 | 2026-07-30 | 2026-09-22 |
| Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer SHR-1701 neoadjuvant - CRC (Colorectal Cancer) | Phase 2 | Recruiting | Hong Qiu | 48 | 2025-12-20 | 2026-03-17 |
| A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation GFH375 - Advanced Solid Tumors Cancer, PDAC | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 126 | 2025-10-21 | 2025-12-02 |
| A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors GFH276 - Cancer, PDAC | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 450 | 2025-09-22 | 2025-09-30 |
| PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer PM8002, Chemotherapy Regimen 1, Chemotherapy Regimen 2 - CRC (Colorectal Cancer) | Phase 2 | Recruiting | Biotheus Inc. | 100 | 2025-08-19 | 2026-07-23 |
| An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. NGM120 Q4W, NGM120 Q8W, Placebo given - Colorectal Cancer, CRC (Colorectal Cancer) | Phase 2 | Recruiting | NGM Biopharmaceuticals, Inc | 136 | 2025-06-25 | 2026-04-01 |
| Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors Decoy20, Tislelizumab - Solid Tumor, Adult, HCC - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Active not recruiting | Indaptus Therapeutics, Inc | 120 | 2023-02-28 | 2026-01-13 |
| Study of Ruxolitinib in Colorectal Cancer Patients Ruxolitinib, Regorafenib, Placebo - CRC (Colorectal Cancer) | Phase 2 | Terminated | Incyte Corporation | 396 | 2014-03-01 | 2018-02-13 |
Colorectal Neoplasms (10) · Colonic Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Neoplasm, Residual (1) · Neoplasms (1)
Colonic Diseases (10) · Digestive System Diseases (10) · Digestive System Neoplasms (10) · Gastrointestinal Diseases (10) · Gastrointestinal Neoplasms (10) · Intestinal Diseases (10) · Intestinal Neoplasms (10) · Neoplasms by Site (10) · Rectal Diseases (10) · Neoplasms (9) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Bronchial Neoplasms (1)
26S proteasome non-ATPase regulatory subunit 13 (1) · Bevacizumab (1) · Cetuximab (1) · DMAC2L protein, human (1) · Gemcitabine (1) · Taxes (1) · regorafenib (1) · ruxolitinib (1) · tislelizumab (1)
Genfleet Therapeutics (Shanghai) Inc. (2) · Incyte Corporation (2) · Biotheus Inc. (1) · Hong Qiu (1) · Indaptus Therapeutics, Inc (1) · NGM Biopharmaceuticals, Inc (1) · Sun Yat-sen University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
China (6) · United States (3) · South Korea (2) · Australia (1) · France (1) · Georgia (1) · Germany (1) · Israel (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Albert Assad (1) · Kaixiong Tao, MD (1) · Lin Shen, MD (1) · Ruihua Xu, PhD, MD (1) · Tao Zhang, MD (1)